论文部分内容阅读
对８１例原发性肝癌（ＨＣＣ）病人进行了血清过氧化物酶（ＰＯＤ）的测定，并以良性肝病和正常人为对照。结果表明，ＨＣＣ组血清ＰＯＤ活性明显高于对照组（Ｐ＜０．０１），而正常人与肝硬化、病毒性肝炎和良性肝占位病人血清ＰＯＤ活性之间无显著性差异（Ｐ＜０．０５）。血清ＰＯＤ诊断ＨＣＣ的阳性率为５６．８％，特异性为９３．６％。血清ＰＯＤ与ＡＦＰ联合检测，可提高对ＨＣＣ的诊断率。血清ＰＯＤ检测还可用于ＨＣＣ的早期诊断，术后疗效观察和ＨＣＣ与良性肝脏疾病的鉴别诊断。
The serum peroxidase (POD) was measured in 81 patients with primary liver cancer (HCC) and compared with benign liver disease and normal controls. The results showed that serum POD activity was significantly higher in the HCC group than in the control group (P<0.01), but there was no significant difference in serum POD activity between normal subjects and patients with liver cirrhosis, viral hepatitis, and benign liver lesions (P<0). .05). The positive rate of serum POD in the diagnosis of HCC was 56.8%, and the specificity was 93.6%. Combined detection of serum POD and AFP can increase the diagnostic rate of HCC. Serum POD assay can also be used for early diagnosis of HCC, postoperative efficacy observation and differential diagnosis of HCC and benign liver disease.